 I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy CHOEP- cyclophosphamide, doxorubicin doxorubicin hydrochloride, etoposide, vincristine vincristine sulfate and prednisone in patients with newly diagnosed stage II, III and IV peripheral T-cell lymphoma not otherwise specified NOS, anaplastic large cell lymphoma anaplastic lymphoma receptor tyrosine kinase ALK negative ALK positive if International Prognostic Index IPI 3, 4, or 5, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma or hepatosplenic gamma delta T-cell lymphoma. 